ENLV (ENLV) Stock Price & Analysis
ENLV (ENLV) fell 3.02% to USD 0.69 as of June 10, 2026 at 07:10 UTC, according to Nexqual real-time market data.
ENLV last closed at USD 0.71; the session ranged USD 0.68–0.74 on volume of 355,537 shares. Market capitalization is $166.95M, with a 52-week range of USD 0.66–2.1 (NCM). Source: Nexqual, June 10, 2026 at 07:10 UTC.
Key Statistics (as of June 10, 2026 at 07:10 UTC)
| Price | USD 0.69 |
|---|---|
| Change | ▼ 3.02% (down) |
| Previous Close | USD 0.71 |
| Open | USD 0.72 |
| Day Range | USD 0.68 – 0.74 |
| 52-Week Range | USD 0.66 – 2.1 |
| Volume | 355,537 shares |
| Market Cap | $166.95M |
| Exchange | NCM |
Technical Analysis (ENLV)
Nexqual's technical model rates ENLV "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 07:10 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 40.01 (neutral) |
| vs SMA50 | Below (USD 0.83) |
| MACD | -0.02 (negative) |
Analyst Ratings (ENLV)
Wall Street analysts rate ENLV "None" based on 1 analysts, with a mean price target of USD 20 (range USD 20–20), per Nexqual as of June 10, 2026 at 07:10 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 20 |
| High Target | USD 20 |
| Low Target | USD 20 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (ENLV)
| EPS Estimate | USD -0.01 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.09 vs est -0.03 ▼ miss |
| 2025-09-30 | USD -0.09 vs est -0.12 ▲ beat |
| 2025-06-30 | USD -0.08 vs est -0.16 ▲ beat |
| 2025-03-31 | USD -0.15 vs est -0.16 ▲ beat |
Source: Nexqual, June 10, 2026 at 07:10 UTC.
Financials & Fundamentals (ENLV)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | +126.17% |
| Debt / Equity | 0.03 |
| Current Ratio | 193.24 |
| Total Cash | $5.75M |
| Total Debt | $641,000 |
| Free Cash Flow | $-1.74B |
Source: Nexqual, June 10, 2026 at 07:10 UTC.
Financial Health Score (ENLV)
Nexqual rates ENLV's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 07:10 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $6M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$10M |
| Efficiency | Strong — ROE 126%, ROA -0.8% |
Ownership (ENLV)
| Insider Ownership | +85.26% |
|---|---|
| Institutional Ownership | +1.51% |
| Shares Outstanding | 241.05M |
| Float | 57.72M |
| Short % of Float | +0.17% |
Source: Nexqual, June 10, 2026 at 07:10 UTC.
Leadership (ENLV)
ENLV is led by Oren Hershkovitz (age 48), Chief Executive Officer, per Nexqual as of June 10, 2026 at 07:10 UTC.
| Chief Executive Officer | Oren Hershkovitz (age 48) |
|---|---|
| Executive Chairman | Shai Novik (age 59) |
| Chief Financial Officer | Shachar Shlosberger (age 48) |
| Senior Director of Operations | Veronique Amor-Baroukh |
| Director of Human Resources | Sigal Arad |
Major Backers & Investors (ENLV)
Notable institutional backers of ENLV include ARK Invest, Diametric Capital, Lp, Prelude Capital Management LLC, according to Nexqual as of June 10, 2026 at 07:10 UTC.
Active Investors
| Investor | Stake |
|---|---|
| ARK Invest | 16.21% |
| Diametric Capital, Lp | 7.99% |
| Prelude Capital Management LLC | 1.22% |
| Two Sigma Investments, LP | 0.79% |
| UBS Group AG | 0.75% |
| Fidelity | 0.73% |
| Bank of America Corporation | 0.7% |
| Renaissance Technologies | 0.69% |
Source: Nexqual, June 10, 2026 at 07:10 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KMDA | Kamada Ltd. | USD 7.24 | ▲ 0.98% |
| EVGN | Evogene Ltd. | USD 0.6 | ▼ 3.71% |
| ENTX | Entera Bio Ltd. | USD 1.22 | ▲ 3.39% |
| RDHL | Redhill Biopharma Ltd. | USD 0.8 | ▼ 22.33% |
| EDSA | Edesa Biotech, Inc. | USD 4.94 | ▼ 9.52% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:10 UTC. This page is informational and not investment advice.